Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.53 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 7/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390098 | 0.91 | NAMPT (0.51) | NAMPTKDM1AROCK2SPRSCN9A | |
| SCHEMBL2387834 | 0.90 | NAMPT (0.65) | NAMPTKDM1AROCK2SPRPROKR1 | |
| SCHEMBL2388766 | 0.90 | NAMPT (0.55) | NAMPTKDM1AROCK2SPRSCN9A | |
| SCHEMBL2389804 | 0.90 | NAMPT (0.55) | NAMPTKDM1AROCK2SPRSCN9A | |
| SCHEMBL2390814 | 0.90 | NAMPT (0.56) | NAMPTKDM1AROCK2SPRSCN9A | |
| SCHEMBL2390868 | 0.89 | NAMPT (0.54) | NAMPTROCK2EPHX2SPRSCN9A | |
| SCHEMBL2390745 | 0.88 | NAMPT (0.54) | NAMPTKDM1AROCK2SPRSCN9A | |
| SCHEMBL2387611 | 0.87 | NAMPT (0.54) | NAMPTKDM1AROCK2SPRSCN9A | |
| SCHEMBL2390063 | 0.87 | NAMPT (0.55) | NAMPTKDM1AROCK2SPRSCN9A | |
| SCHEMBL2388919 | 0.86 | ROCK2 (0.61) | NAMPTKDM1AROCK2SPRSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | claimed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | claimed |
| EP-2375904-B1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230498-A1 | BIARYL CARBOXAMIDES | PAFAH1B3, PAFAH1B2, FAAH2 | NAMPT 2170/4885KDM1A 2272/4885ROCK2 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.